Haynes Barton F, Shaw George M, Korber Bette, Kelsoe Garnett, Sodroski Joseph, Hahn Beatrice H, Borrow Persephone, McMichael Andrew J
Department of Medicine, Duke University, Durham, NC 27710, USA; Department of Immunology, Duke University, Durham, NC 27710, USA; Duke University Human Vaccine Institute, Duke University, Durham, NC 27710, USA.
Departments of Medicine and Microbiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
Cell Host Microbe. 2016 Mar 9;19(3):292-303. doi: 10.1016/j.chom.2016.02.002. Epub 2016 Feb 25.
Development of an effective AIDS vaccine is a global priority. However, the extreme diversity of HIV type 1 (HIV-1), which is a consequence of its propensity to mutate to escape immune responses, along with host factors that prevent the elicitation of protective immune responses, continue to hinder vaccine development. Breakthroughs in understanding of the biology of the transmitted virus, the structure and nature of its envelope trimer, vaccine-induced CD8 T cell control in primates, and host control of broadly neutralizing antibody elicitation have given rise to new vaccine strategies. Despite this promise, emerging data from preclinical trials reinforce the need for additional insight into virus-host biology in order to facilitate the development of a successful vaccine.
开发一种有效的艾滋病疫苗是全球的首要任务。然而,1型人类免疫缺陷病毒(HIV-1)的极端多样性,这是其为逃避免疫反应而发生突变的倾向的结果,再加上阻止引发保护性免疫反应的宿主因素,继续阻碍着疫苗的开发。在对传播病毒的生物学、其包膜三聚体的结构和性质、灵长类动物中疫苗诱导的CD8 T细胞控制以及广泛中和抗体诱导的宿主控制的理解方面取得的突破,催生了新的疫苗策略。尽管有这些希望,但临床前试验的新数据强化了进一步深入了解病毒-宿主生物学的必要性,以便推动成功疫苗的开发。